Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.
Nasal polyps
chronic sinusitis
dexpramipexole
eosinophils
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
10
08
2018
accepted:
20
08
2018
pubmed:
5
10
2018
medline:
21
5
2019
entrez:
5
10
2018
Statut:
ppublish
Résumé
Chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia is a disease of the upper respiratory tract for which few therapies are available. Because the oral investigational drug dexpramipexole serendipitously decreased blood eosinophils in amyotrophic lateral sclerosis studies, we assessed its safety, eosinophil-lowering activity, and preliminary clinical efficacy in patients with CRSwNP and eosinophilia. Sixteen subjects with CRSwNP, absolute eosinophil count (AEC) ≥ 0.300 × 10 Thirteen of 16 subjects completed 6 months of dexpramipexole treatment. Geometric mean baseline AEC was 0.525 ± 0.465 eosinophils × 10 Dexpramipexole treatment produced profound eosinophil-lowering in peripheral blood and nasal polyp tissue. Despite the near-elimination of polyp eosinophils, decreased TPS and nasal symptom improvement were not observed. 2 Laryngoscope, 129:E61-E66, 2019.
Substances chimiques
Antioxidants
0
Pramipexole
83619PEU5T
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E61-E66Subventions
Organisme : Knopp Biosciences, LLC.
Pays : International
Informations de copyright
© 2018 The American Laryngological, Rhinological and Otological Society, Inc.